Insider Buying: (Mauritius) Pte Ltd Maxwell Buys 1,600,000 Shares of Portola Pharmaceuticals Stock (PTLA)

Portola Pharmaceuticals (NASDAQ:PTLA) major shareholder (Mauritius) Pte Ltd Maxwell acquired 1,600,000 shares of the stock in a transaction that occurred on Wednesday, October 8th. The stock was purchased at an average price of $26.00 per share, for a total transaction of $41,600,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

PTLA has been the subject of a number of recent research reports. Analysts at Zacks downgraded shares of Portola Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday. They now have a $31.10 price target on the stock.

Shares of Portola Pharmaceuticals (NASDAQ:PTLA) opened at 26.55 on Friday. Portola Pharmaceuticals has a 1-year low of $19.59 and a 1-year high of $31.48. The stock has a 50-day moving average of $26.88 and a 200-day moving average of $25.39. The company’s market cap is $1.099 billion.

Portola Pharmaceuticals (NASDAQ:PTLA) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.79) by $0.03. The company had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.44 million. Portola Pharmaceuticals’s revenue was down 7.2% compared to the same quarter last year. Analysts expect that Portola Pharmaceuticals will post $-3.38 EPS for the current fiscal year.

Portola Pharmaceuticals, Inc (NASDAQ:PTLA) is a biopharmaceutical company developing product candidates that have the potential to represent advances in the fields of thrombosis and hematology.


Contact WE

16 Morcellement des Mascareignes,
Gajadhur Lane,Trou aux Biches,
MAURITIUS
tel.: +2309104667
e-mail: info@w-e-consult.com